Loading
SH
Starpharma Holdings Limited Stock: price and insider trades · Australia
5 insiders bought €189k of shares over the last 90 days, the latest filed 13 Aug 2026.
Starpharma Holdings Limited: what insiders have been doing
Headquartered in Melbourne, Australia, Starpharma Holdings Limited is a listed company and traces its origins to 1996. Filings by its managers are published through ASX. Over the twelve months to 18 October 2026, the company's managers filed 17 filings, from 9 insiders.
The record shows 5 purchases on the open market worth €189k, made by 5 insiders, against 1 sale by 1 insider. The totals do not cover 1 filing with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €122k, bought by Robert B. Thomas and made public on 13 August 2026 (0.057% of market cap). On the buying side, the filings list 5 senior executives among the declarants.
Within a 30-day window, 4 purchases overlapped with buying by a second insider. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last purchase on record was published on 13 August 2026, which is 66 days ago. Typically, a trade is published a median of 2 days after it takes place. The shorter that gap, the sooner other investors can see what insiders have done.
Compared with its exchange (2,222 companies, median 3 filings), a count of 17 filings is above the norm. The full history, which starts in 2026, counts 5 purchases against 1 sale.
Source: insider filings from ASX. Past trades are no guide to future returns.
Key facts
Headquarters: Melbourne, Australia · Founded: 1996
Source: Wikidata (CC0).
Insider Decl.
17
Thresholds
n/a
Buy Volume
€189,166
5 ops. · all time
Sell Volume
n/a
1 ops. · all time
Who traded when
BuySaleCheryl Maley1 buy1 sale
Dr Jeff Davies1 buy
Dr Russell Basser1 buy
Lynda Cheng1 buy
Robert B. Thomas1 buy
Since the insiders bought
- +5.7%Entry A$0.70 · Close at T+30 A$0.74
- +5.7%Entry A$0.70 · Close at T+30 A$0.74
- +5.7%Entry A$0.70 · Close at T+30 A$0.74
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,845 of 24,148 companies
32.4
score / 100
Value30
Quality35
FCF yld-0.9%
Earn yld-1.9%
EV/EBITDA·
ROE-46%
Gross mgn94%
Net mgn-62%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
A$0.82
Analyst consensus
1 analystsA$1.25Target A$1.25(+53%)A$1.25
Income statement
RevenueA$12.1M
Gross profitA$11.3M94% margin
EBITDA-A$8.1M-67% margin
Net income-A$7.5M-58.9% margin
Valuation
PER (forward)28.2x
P/Book24.8x
Beta0.76
Balance sheet & cash
Market capA$389.8M
Total debtA$707k
Free Cash Flow-A$3.5M
Debt / Equity5%
Profitability & ownership
ROE-45.6%
ROA-21.0%
% insiders29.9%
% institutions18.5%
Last declaration on 4 October 2026
Declarations17 total
702,768 sharesShareASXISIN AU000000SPL0ASX:2924-03144254-3A703305
ShareASXISIN AU000000SPL0ASX:2924-03140195-3A702573
ShareASXISIN AU000000SPL0ASX:2924-03138319-3A702279
ShareASXISIN AU000000SPL0ASX:2924-03135753-3A701801
ShareASXISIN AU000000SPL0ASX:2924-03134783-3A701612
ShareASXISIN AU000000SPL0ASX:2924-03125113-3A699640
ShareASXISIN AU000000SPL0ASX:2924-03123046-3A699198
ShareASXISIN AU000000SPL0ASX:2924-03122452-3A699067
ShareASXISIN AU000000SPL0ASX:2924-03120961-3A698781
36,191 shares@ A$0.570.0059% mcap100.0% of flowShareASXISIN AU000000SPL0ASX:2924-03120793-3A698758
Canonical exit: 9 Nov 2026 (T+90)
350,001 shares@ A$0.570.057% mcap100.0% of flowShareASXISIN AU000000SPL0ASX:2924-03120791-3A698757
Canonical exit: 9 Nov 2026 (T+90)
22,741 shares@ A$0.570.0037% mcap100.0% of flowShareASXISIN AU000000SPL0ASX:2924-03120790-3A698756
Canonical exit: 9 Nov 2026 (T+90)
117,291 shares@ A$0.570.019% mcap100.0% of flowShareASXISIN AU000000SPL0ASX:2924-03120788-3A698754
Canonical exit: 9 Nov 2026 (T+90)
16,667 shares@ A$0.570.0027% mcap100.0% of flowShareASXISIN AU000000SPL0ASX:2924-03120784-3A698752
Canonical exit: 9 Nov 2026 (T+90)
ShareASXISIN AU000000SPL0ASX:2924-03120049-3A698599
ShareASXISIN AU000000SPL0ASX:2924-03112892-3A697443
ShareASXISIN AU000000SPL0ASX:2924-03103049-3A695823
17 of 17 declarations
About Starpharma Holdings Limited
Starpharma Holdings Limited is an Australian biopharmaceutical company focused on developing drugs based on its proprietary polymer technology. It targets treatments for cancer and viral infections.
